1. Introduction {#s0005}
===============

Cognitive impairment is a core feature of schizophrenia with a negative prognostic value for global functioning, social skills, poorer self-care, and independent living skills ([@bb0005]; [@bb0060]; [@bb0165]; [@bb0155]). In addition, cognitive deficits reduce the potential benefit of rehabilitation programs, even when high-quality rehabilitation is provided, contributing to higher rates of institutionalization ([@bb0020]; [@bb0205]; [@bb0330]). It is for these reasons that cognitive training techniques were developed, in the hope that improving cognition would lead to lasting functional outcome improvements.

Cognitive remediation (CR) is "an intervention targeting cognitive deficit using scientific principles of learning with the ultimate goal of improving functional outcomes" (Cognitive Remediation Experts Workshop, 2012, p. 1). In the meta-analysis conducted by [@bb0365], CR was found to have a moderate but durable effect on global cognition and functional outcomes. In addition, functioning was improved most when CR was combined with other forms of rehabilitation.

Although CR is an effective approach, there is evidence that as many as one in four participants receiving this intervention will not improve ([@bb0245]; [@bb0365]). While many studies have focussed on the evaluation of CR efficacy, only a limited number have considered how individual characteristics, clinical presentation, and other factors may affect treatment response ([@bb0135]; [@bb0225]; [@bb0305]; [@bb0315]). [@bb0340] suggested that these types of studies are important to improve the personalisation agenda of CR even if the results are negative. Systematic evidence on mediators and moderators may allow tailoring therapy according to patients\' characteristics in order to maximise its potential benefits.

To date, there is no systematic review of the putative factors which may affect CR response, although some have been suggested in the literature. For instance, a number of studies have suggested that the individuals most likely to benefit from CR are younger ([@bb0210]; [@bb0360]), with fewer symptoms ([@bb0365]) and, more severe cognitive difficulties ([@bb0260]; [@bb0365]). However, these characteristics have been identified in single studies using underpowered samples. There is limited converging evidence, with some studies suggesting that higher or lower levels of a characteristic (e.g. functioning) may be important in influencing therapy outcomes ([@bb0120]; [@bb0305]). Further, studies have considered therapy moderators and mediators in relation to different therapy outcomes (e.g. different cognitive domains, functioning, motivation) contributing to the limited consensus in identifying reliable factors that can be used to tailor CR.

Despite the limited evidence, a number of authors ([@bb0100]; [@bb0195]; [@bb0230]; [@bb0285]) have highlighted the importance of developing a more individualized treatment to improve therapy response. [@bb0145] attempted to personalise CR by adapting training on modules participants received in relation to their initial cognitive assessment (e.g. receiving more training for the most compromised domain). These authors compared the personalised approach to general CR training but found no differences between the two methods suggesting that this personalisation method may not bring about benefits.

While personalisation is increasingly found important, there is no systematic evidence in the literature summarizing relevant findings that may be able to guide future studies. The current review aims to identify potential individual factors at baseline, moderators, that may predict treatment outcomes and that may be used to tailor CR and improve its benefits.

2. Methods {#s0010}
==========

2.1. Research evidence identification {#s0015}
-------------------------------------

For this review, we followed the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines ([@bb0240]). The review protocol was registered on a public database (e.g. <https://www.crd.york.ac.uk/prospero/>) on the 27th of February 2018. Searches were conducted up to the 16th of January 2019 on PsycInfo and PubMed databases. We also searched potentially relevant websites including ResearchGate and Mendeley.

In order to identify any additional relevant papers, the reference lists of included studies, relevant and recent reviews (e.g. [@bb0335]; [@bb0365]; [@bb0040]; [@bb0085]), and relevant articles in this field were also inspected.

2.2. Literature search {#s0020}
----------------------

A broad search string strategy was adopted including the following terms: "exp. schizophrenia" OR "exp. psychosis" OR "exp. schizoaffective disorder" AND "cognitive enhancement" OR "cognitive rehabilitation" OR "cognitive remediation" OR "cognitive training".

2.3. Inclusion criteria {#s0025}
-----------------------

Eligible studies:•Randomized controlled trials.•Assessed the relationship of one or more baseline moderators to CR treatment response. Moderators, according to [@bb9000], are all those factors that identify for whom and under which circumstances treatments have different effects (e.g. age, cognitive profile).•Included participants over the age of 18 with a diagnosis of schizophrenia or schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorder ([@bb0010]), Research Diagnostic Criteria ([@bb0290]) or International Classification of Diseases ([@bb0325]).•The sample considered had at least 75% of participants with a diagnosis of schizophrenia or schizoaffective disorders.•The study was in English language.•The CR interventions adopted use principles such as massed practice, errorless learning, and scaffolding to improve cognition and/or social cognition and/or functioning. All modes of administration (computer, pen and paper, individual, group, presence or absence of therapist) were considered.

2.4. Exclusion criteria {#s0030}
-----------------------

We excluded all study designs that were not randomized controlled trials (e.g. case studies and opinion papers) or were a combination of randomized and non-randomized controlled trials \[e.g. the study conducted by [@bb0160]\]. We also excluded studies where the focus of the intervention was psychoeducation about cognitive difficulties.

2.5. Study selection and data extraction {#s0035}
----------------------------------------

Two authors (BS and DT) independently conducted a screening of all titles and abstracts to identify eligible studies. Disagreements during the selection process were resolved by consultation with a third author (MC).

For all the included studies the following information was extracted:•sample size for the experimental and control condition;•demographic characteristics including age, gender, years of education, and duration of illness;•details of the intervention and control condition;•type of moderator considered;•study primary and secondary outcomes;•reported effect of the moderator on the outcome.

2.6. Quality assessment {#s0040}
-----------------------

All included studies were assessed for methodological rigor using the Clinical Trials Assessment Measure (CTAM) ([@bb0355]). This is a 15-item measure of trial methodology specifically developed for psychological treatment studies. The maximum score is 100 and studies with a CTAM score \< 65 are considered at higher risk of bias ([@bb0355]). All studies were independently rated by two authors (BS and KN) and discrepancies resolved by consultation with a third author (MC). CTAM scores were checked with the study authors and adjusted according to their feedback if provided.

3. Results {#s0045}
==========

As shown in the PRISMA diagram ([Fig. 1](#f0005){ref-type="fig"}), the literature search identified thirty-six eligible studies, including 2737 participants. A summary of the studies characteristics is reported in [Table 1](#t0005){ref-type="table"}.Fig. 1Systematic search PRISMA diagram.Fig. 1Table 1Characteristics of the included studies.Table 1StudyStudy designOriginal paperTitleModerator investigatedParticipantsInterventionPrimary outcome measuresSecondary outcome measuresMean age (SD)Male (%)Sample size N (CR)Mean years of education (SD)Total included in analysis (dropouts; interventions)Years of illness (mean)Setting (inpatients, outpatients)Treatment interventionControl intervention[@bb0090], USASecondary analysis of RCTs (Kurtz et al., 2007, 2015)Kurtz et al., 2007Computer-assisted cognitive remediation in schizophrenia: what is the active ingredient?Age, duration of illness32.96 (11.57)70.5%11212.82 (2.40)1129.34OutpatientsCognitive remediationComputer skills trainingWorking memory, functioning and symptomsNRKurtz et al., 2015Social skills training and computer-assisted cognitive remediation in schizophrenia.[@bb0210], USASecondary analysis of two RCTsMcGurk et al., 2005Cognitive training and supported employment for persons with severe mental illness: one-year results from a randomized controlled trialAgeNR55.26%76 (37)NR76NRNRCognitive training + vocational rehabilitationsVocational rehabilitationsCognitive functioning; symptomsNR(McGurk et al., 2005 and McGurk et al., 2015)McGurk et al., 2015Cognitive enhancement treatment for people with mental illness who do not respond to supported employment: a randomized controlled trial[@bb0360], UKSecondary analysis of RCT (Wykes, Reeder, Landau et al., 2007)Wykes, Reeder, Landau et al., 2007Cognitive remediation therapy in schizophrenia: a randomized controlled trialAge36 (NR)73%85 (43)Young = 11.85Memory: 75 PT; 68FUNRNRCognitive remediation (paper and pencil) + treatment as usualTreatment as usualMemory, cognitive flexibility and planningSocial functioning, symptoms, self-esteemOlder = 10.8Flexibility: 72 PT; 64 FUPlanning: 74 PT; 67 FUSelf-esteem: 75 PT; 67 FUSymptoms: 79 PT; 69 FUSocial functioning: 77 PT; 74 FU[@bb0145], UKRCT//Age; intellectual33.54 (6.9)73%138 (65)NR92NROutpatientsCognitive remediation therapyRECOS programBADS (Behavioural Assessment of Dysexecutive Syndrome)Cognition and clinical measures[@bb0015], USASecondary analysis of RCT (Medalia et al., 2000)Medalia et al., 2000Remediation of memory disorders in schizophreniaSymptoms36.7759.26%54 (36)10.99NRNRInpatientsCognitive remediation exercises + standard hospital careTreatment as usualCognitive functioning; symptomsNR[@bb0345], UKRCT//Medication; demographics (age, gender); and symptoms38.5575.75%33 (17)12.3533NROutpatientsCognitive Remediation Therapy + standard rehabilitation treatmentIntensive occupational therapyWorking memory; cognitive flexibility and planningSocial functioning, symptoms, and self-esteem.[@bb0350], UKRCT//Medication36 (NR)73%85 (43)NRNRNRNRCognitive remediation therapyTreatment as usualWorking memory; cognitive flexibility and planningSocial functioning, symptoms, self-esteem[@bb0050], ItalyRCT//COMT alleleNR68%50 (27)NR49NROutpatientsFunction-specific computer-aided exercises + standard rehabilitation treatmentStandard rehabilitation treatmentSymptoms; functioning; cognitive flexibility; sustained attentionNR[@bb0120], SpainSecondary analysis of RCT, Farreny et al., 2012Farreny et al., 2012REPYFLEC cognitive remediation group training in schizophrenia Looking for an integrative approachDemographics (sex, age, education); illness duration; medication; cognition; symptoms and functioning39.5 (8.5)65.5%62 (29)NRNR17.6OutpatientsREPYFLECStimulating activities focused on leisure and socialisationNeurocognition functioning symptomsNR[@bb0115], SpainSecondary analysis of RCT, Farreny et al., 2012Farreny et al., 2012REPYFLEC cognitive remediation group training in schizophrenia looking for an integrative approachBaseline negative symptoms and executive function40.6 (7.6)68%62 (29)NRNRNROutpatientsREPYFLECLeisure activitiesNeurocognition functioning symptomsNR[@bb0250], USASecondary analysis of 2 RCTs (Fisher et al., 2009, 2015)Fisher et al., 2009Using neuroplasticity-based auditory training to improve verbal memory in schizophreniaCOMT allele33.6 (13.1)70.8%48 (48)NRNR12.9OutpatientsPosit science auditory trainingComputer gameGlobal cognitionNRFisher et al., 2015Neuroplasticity-based auditory training via laptop computer improves cognition in young individuals with recent onset schizophrenia[@bb0255], SpainSecondary analysis of RCT (Penadés et al., 2013)Penadés et al., 2013Brain effects of cognitive remediation therapy in schizophrenia: a structural and functional neuroimaging study.Demographic variables (age; education; duration of illness; number of hospitalisations) medication; baseline brain structure; baseline symptoms; baseline cognitive performance36.2274%50 (17)13.34NR12.84OutpatientsCognitive remediation therapySocial skills training and healthy control groupCognitionNR[@bb0305], USASecondary analysis of RCT (Twamley et al., 2012)Twamley et al., 2012Compensatory Cognitive Training for psychosis: effects in a randomized controlled trialDemographic variables (age; gender; education; diagnosis; duration of illness); medication; symptoms; cognition; functioning; self-reported cognitive and functioning problems; intelligence47.3 (9.8)65%8913.3 (1.8)8912.7OutpatientsCompensatory Cognitive Training (CCT) + standard pharmacotherapyStandard pharmacotherapyCognition; functioning, symptomsNR[@bb0025], USARCT//Baseline community function4054%77 (38)NR72NROutpatientsNeurocognitive enhancement therapy + vocational programVocational programCompetitive employment rates and hours of competitive employmentNR[@bb0030], USASecondary analysis from RCTBell et al. 2008Neurocognitive enhancement therapy with vocational services: work outcomes at two-year follow-up.Baseline community functionCR high community functioning = 40.35 (10.48)CR high community functioning = 48%175 (99)CR high community functioning = 12.26 (1.57)174NROutpatientsNeurocognitive enhancement therapy + vocational programVocational programCompetitive employment rates and hours of competitive employmentNRCR low community functioning = 40.07 (8.96)CR low community functioning = 55%CR low community functioning = 12.20 (2.04)SE high community functioning = 42.51 (10.69)SE high community functioning = 53%SE high community functioning = 13.57 (2.68)SE low community functioning = 41.28 (10.28)SE low community functioning = 72%SE low community functioning = 12.57 (2.44)[@bb0065], USASecondary analysis of RCT (Twamley et al., 2012)Twamley et al., 2012Compensatory Cognitive Training for psychosis: effects in a randomized controlled trialNeurocognitive insight46.3 (9.7)65.2%6912.9 (1.7)4323.3OutpatientsCompensatory Cognitive Training + standard pharmacotherapyStandard pharmacotherapyCognition and functioningNR[@bb0070], USASecondary analysis of RCT (Twamley et al., 2012)Twamley et al., 2012Compensatory Cognitive Training for psychosis: effects in a randomized controlled trialCOMT allele48 (8.6)65.9%41 (20)13.1 (1.7)4123.8OutpatientsCompensatory Cognitive Training + standard pharmacotherapyStandard pharmacotherapyCognition, functioning, symptomsNR[@bb0110], NorwayRCT//Global functioning, self-esteemCBT = 33.2 (8.0)CBT = 61.8%148 (64)NR148CBT = 8.1NRVocational rehabilitation augmented + CRVocational rehabilitation augmented + CBTSelf-esteem; global functioning; depression; employment statusNRCR = 32.4 (7.9)CR = 79.4%CR = 5.9[@bb0140], USARCT//Intellectual (pre-morbid and morbid)42.82 (8.66)80%152 (72)13.38 (3.03)151NROutpatientsNeurocognitive enhancement therapy with work therapyWork therapyCognitive functioningNR[@bb0095], USASecondary analysis of RCT (Fiszdon et al., 2016)Fiszdon et al., 2016Cognitive remediation for individuals with psychosis: efficacy and mechanisms of treatment effectsLearning potentialCR = 47.3 (9.1)CR = 78.4%75 (50)CR = 12.5 (1.8)75NROutpatientsCognitive remediationTreatment as usualCognitionNRTAU = 48.9 (9.9)TAU = 62.5%TAU = 12.1 (2.3)[@bb0180], USASecondary analysis of RCT (Eack et al., 2009)Eack et al., 2009Cognitive enhancement therapy for early-course schizophrenia: effects of a two-years randomized controlled trial.Cortical reserve25.72 (5.94)64%58NR503.26NRCognitive enhancement therapyEnriched supportive therapyCognition and social cognitionNR[@bb0190], USASecondary analysis of RCT (Kurts et al., 2007)Kurts et al., 2007Computer-assisted cognitive remediation in schizophrenia: what is the active ingredient?Cognition, symptoms32.4 (11.2)69%3613.4 (1.9)368.7OutpatientsCognitive remediationComputer-skills trainingCognition, functioning, symptomsNR[@bb0185], USARCT//Cognition, symptoms, functioning34.6 (10.0)72%4613.4 (1.9)239.6OutpatientsCognitive remediationComputer-skills trainingFunctioningNR[@bb0270], SwitzerlandSecondary analysis of RCT (Rodewald et al. 2011)Rodewald et al. 2011Planning and problem-solving training for patients with schizophrenia: a randomized controlled trial.Cognition, symptoms, motivationProblem-solving training = 28.0 (7.0)Problem-solving training = 84%77Problem-solving training = 14.7 (2.9)75Problem-solving training = 5.0InpatientsTraining of planning and problem-solving ability (PLAN)Basic cognitive trainingCognitionNRBasic cognition training = 29.5 (7.4)Basic cognition training = 77%Basic cognition training = 15.6 (3.7)Basic cognition training = 3.8[@bb0295], USARCT//Brain Structure (White matter integrity)HC = 41.41 (11.74)HC = 60.71%HC (*N* = 28)HC = 15.15 (2.67)HC (N = 28)24.52OutpatientsTargeted Cognitive training + Social Cognitive TrainingTargeted Cognitive trainingCognition and symptoms,NRSZ = 45.59 (10.25)SZ = 68.75%SZ (*N* = 48)SZ = 45.59 (10.25)SZ (*N* = 30)[@bb0125], USARCT//MotivationComputerized auditory training = 21.70 (3.26)Computerized auditory training = 72.09%121 (63)Computerized auditory training = 12.88 (1.60)86NROutpatientsComputerized auditory trainingComputer gameCognition, symptoms, functioning and reward anticipationNRComputer game = 20.74 (3.37)Computer game = 76.74%Computer game = 12.86 (2.10)[@bb0310], USASecondary analysis of RCT (Twamley et al., 2012)Twamley et al., 2012Compensatory Cognitive Training for Psychosis: Effects in a Randomized Controlled TrialMedication (Serum anticholinergic activity)43.86 (10.29)71%49 (25)13.08 (2.20)49NROutpatientsNeuroplasticity-Based Computerized Auditory TrainingComputer gameCognition and symptomsNR[@bb0105], USASecondary analysis of RCT (Fiszdon et al., 2016)Fiszdon et al., 2016Cognitive remediation for individuals with psychosis: efficacy and mechanisms of treatment effectsAge38.10%63 (35)CR = 12.2 (1.8)63NRNRComputer-assisted cognitive remediationComputer gameCognition and functioningSelf-described cognitive performance and symptomsCR = 46.9 (6.6)Control = 12.8 (1.3)Control = 48.5 (8.8)[@bb0130], USARCT//SymptomsNET + WT = 41.9 (9.9)NET + WT = 76%94 (45)NET + WT = 13.3 (2.1)94NROutpatientsCognitive Remediation Therapy + work therapyWork TherapyMemoryNRWT = 43.2 (8.0)WT = 80%WT = 13.5 (2.2)Control = 33.21 (6.89)Control = 9.66 (2.28)Control = 10.68[@bb0200], USASecondary analysis from 2 RCTHogarty et al., 2006Durability and mechanism of effects of cognitive enhancement therapy.Diagnosis25.9 (6.3)69%58 (31)NR583.2OutpatientsCognitive enhancement therapyEnriched supportive therapyCognition, social cognition, symptoms and social adjustmentNREack et al., 2009Cognitive enhancement therapy for early- course schizophrenia: effects of a two-year randomized controlled trial.[@bb0220], USARCT//Cognition, demographic variables (substance abuse and medication comorbidity)VR + CR = 45.5 (9.58)VR + CR = 61%34VR + CR = 12.22 (2.73)34NROutpatientsVocational Services Program + Cognitive Remediation ProgramVocational Services ProgramCognition, symptoms, comorbidity and employmentNRVR = 42.44 (8.52)VR = 56%VR = 11.75 (1.81)[@bb0275], SpainRCT//Medication, symptomsREHACOP = 33.60 (9.4)REHACOP = 75%92 (38)REHACOP = 9.23 (2.7)84NRInpatientsNeuropsychological rehabilitation (REHACOP) + TAUGroup activities including drawing, reading the daily news, and constructing objects using different materialsCognition, symptoms and functioningNRControl = 36.92 (10.5)Control = 77.1%Control = 10.24 (2.8)[@bb0035], AustraliaRCT//Self-esteem42.047.1%3212.6NRNRNRComputer-assisted cognitive rehabilitation (CACR)Wait-listCognition, symptoms and self-esteemNR[@bb0300], USARCT//Age, symptoms, medication, illness duration35.14 (12.57)47.5%46 (24)11.83 (2.08)4615.68OutpatientsComputerized targeted cognitive training + TAUTAUCognition, auditory perception, and symptomsNR[@bb0150], SpainRCT//Age, medicationTAU = 45.40 (9.77)\
Control active = 46.13 (10.11)\
CRT = 46.68 (9.97)68.5%130 (43)TAU = 10.33 (2.65)\
Control active = 9.53 (3.08)\
CRT = 9.30 (2.86)130TAU = 23.38 (8.63)\
Control active = 22.58 (9.10)\
CRT = 24.30 (8.52)InpatientsComputerized CRTTAU\
Computerized typing program and computerized gamesCognition (executive function and memory)Other cognitive tests and functioning[@bb0265], USASecondary analysis of RCT (Fisher et al. 2015)Fisher et al. 2015Neuroplasticity-based auditory training via laptop computer improves cognition in young individuals with recent onset schizophreniaBrain structure, baseline cognition and symptoms22.27 (4.13)65.9%44 (22)12.64 (2.54)441.70OutpatientsTargeted cognitive trainingComputer gamesSymptoms and cognitionNR

3.1. Sample characteristics {#s0050}
---------------------------

Participants had a mean age of 37.7 years (SD 7.3; range 21.2--48.1), and the majority were men (mean = 66.6%; SD 9.4; range 38.1% - 80.5%), with 13.2 years of education (SD 3.8; range 9.7--30.4). Participants had an average illness duration of 12.6 years (SD 7.8; range 1.7--24.5).

3.2. Study characteristics {#s0055}
--------------------------

The mean sample size was 76 \[(SD 36.9); range 32--175; CR group mean = 41 (SD 18.9); Control group mean = 41.4 (SD 22)\]. Most studies were carried out in the United States (*N* = 23); five studies took place in Spain, four in the United Kingdom and the remaining four in Italy, Australia, Norway, and Switzerland.

3.3. Therapy characteristics {#s0060}
----------------------------

Nineteen studies provided CR alone, five combined CR with another active condition (e.g. vocational rehabilitation, social cognitive training) and twelve combined CR with treatment as usual.

3.4. Control condition {#s0065}
----------------------

Twenty-one studies had an active control condition (e.g. computer game, leisure activities), twelve had treatment as usual or waiting list, two had two control conditions (one active and one passive) and another one had an active control condition and a control group including healthy people.

3.5. Trial quality {#s0070}
------------------

The Clinical Trial Assessment Measure scores for each study are summarised in [Table 2](#t0010){ref-type="table"}. The mean score was 66.1 (SD 11.7; range 44--90) out of a maximum of 100. Only 21 (53%) studies scored above the cut-off of 65, indicating a low risk of bias ([@bb0355]). Problems were sample size (33% were too small) with only three studies having adequately calculated power (7.3%), group allocation was not masked (35%), lack of independent randomization (60%), and lack of treatment fidelity assessment (83%).Table 2Clinical Trial Assessment Measure scores.Table 2StudyStudy designOriginal paperClinical Trial Assessment Measure scoresSample (maximum 10)Allocation procedure (maximum 16)Assessment (maximum 32)Comparison (maximum 16)Analysis (maximum 15)Treatment description (maximum 11)Total score (maximum 100)[@bb0090], USASecondary analysis of RCTs (Kurtz et al., 2007, 2015)Kurtz et al., 200721029109666Kurtz et al., 2015710291011370[@bb0210], USASecondary analysis of two RCTs (McGurk et al., 2005 and McGurk et al., 2015)McGurk et al., 200521626615671McGurk et al., 20157162916111190[@bb0360] UKSecondary analysis of RCT (Wykes, Reeder, Landau et al., 2007)Wykes, Reeder, Landau et al., 20071016296151187[@bb0145], UKRCT/71026105361[@bb0015], USASecondary analysis of RCT (Medalia et al., 2000)Medalia et al., 20002106169649[@bb0345], UKRCT/516166151169[@bb0350], UKRCT/1016296151187[@bb0050], ItalyRCT/21026165362[@bb0120], SpainSecondary analysis of RCT, Farreny et al., 2012Farreny et al., 2012216261011671[@bb0115], SpainSecondary analysis of RCT, Farreny et al., 2012Farreny et al., 2012216261011671[@bb0250], USASecondary analysis of 2 RCTs (Fisher et al., 2009, 2015)Fisher et al., 200971326109671Fisher er al., 20157102610151179[@bb0255], SpainSecondary analysis of RCT (Penadés et al., 2013)Penadés et al., 201321661011651[@bb0305], USASecondary analysis of RCT (Twamley et al., 2012)Twamley et al., 201271326615673[@bb0025], USARCT/71661015660[@bb0030], USASecondary analysis from RCTBell et al., 200871661015660[@bb0065], USASecondary analysis of RCT (Twamley et al., 2012)Twamley et al., 201271326615673[@bb0070], USASecondary analysis of RCT (Twamley et al., 2012)Twamley et al., 201271326615673[@bb0095], USASecondary analysis of RCT (Fiszdon et al., 2016)Fiszdon et al., 20162166611647[@bb0110], NorwayRCT/71016105048[@bb0140], USARCT/7103165344[@bb0180], USASecondary analysis of RCT (Eack et al., 2009)Eack et al., 200971661011656[@bb0190], USASecondary analysis of RCT (Kurts et al., 2007)Kurts et al., 200721029109666[@bb0185], USARCT/71026105664[@bb0270], SwitzerlandSecondary analysis of RCT (Rodewald et al. 2011)Rodewald et al. 201171026105664[@bb0295], USARCT/71016105351[@bb0125], USARCT/710261015674[@bb0310], USASecondary analysis of RCT (Twamley et al., 2012)Twamley et al., 201271326615673[@bb0105], USASecondary analysis of RCT (Fiszdon et al., 2016)Fiszdon et al., 2016716291091182[@bb0130], USARCT/71661015660[@bb0200], USASecondary analysis from two RCTs (Hogarty et al., 2006 and Eack et al., 2009)Hogarty et al., 200671016109658Eack et al., 200971661011656[@bb0220], USARCT/213261011365[@bb0275], SpainRCT/71326105667[@bb0035], AustraliaRCT/21026615665[@bb0300], USARCT/2136615648[@bb0150], SpainRCT/716261611682[@bb0265], USASecondary analysis from one RCT (Fisher et al. 2015)Fisher et al., 20157102610151179

3.6. Moderators affecting treatment response {#s0075}
--------------------------------------------

Twenty studies evaluated at least one moderator; seven assessed two, four evaluated three and, five studies investigated more than three moderators. Taken together, they identified moderators falling into five broad categories: demographic; biological; cognitive and functional; psychological and illness-related aspects. Results for each category are summarised in [Table 3](#t0015){ref-type="table"}.Table 3Summary of identified moderators.Table 3Type of featuresFactorsHow many papersPapersAssociation with CR outcomes YES/NOOutcomesDemographicsGender3[@bb0120]\
[@bb0305]\
[@bb0345]NO/Education3[@bb0120]\
[@bb0255]\
[@bb0305]NO/Age3[@bb0090]\
[@bb0210]\
[@bb0360]YESYounger improve more than older in cognition1[@bb0360]YESYounger improve more than older in negative symptoms and functioning1[@bb0305]YESOlder improve more than younger in memory1[@bb0360]YESOlder improve more than younger in self-esteem1[@bb0105]YESOlder improve more than younger in functioning1[@bb0300]YESOlder improve more than younger in verbal learning4[@bb0120]\
[@bb0145]\
[@bb0255]\
[@bb0345]\
[@bb0105]\
[@bb0150]NO/BiologicalBrain structure1[@bb0180]YESHigher cortical reserve positively moderated social cognition1[@bb0255]YESGreater cortical thickness in the temporal and frontal lobes, linked with greater improvement in verbal memory and non-verbal memory1[@bb0295]YESGreater integrity of white matter in the right front-occipital fasciculus predicted improvements in attention/vigilance\
Greater integrity of right corticospinal tract and bilateral medial lemnisci predicted improvements in executive functioning1[@bb0265]NO/Genetic variable1[@bb0050]YESPeople with Met on active treatment had better outcomes in cognitive flexibility and functioning1[@bb0250]YESAssociation between COMT gene and response in global cognition1[@bb0070]NO/Cognition and functioningIQ1[@bb0140]YESLower IQ associated with cognitive gains1[@bb0145]YESHigher IQ associated with lower cognitive gains1[@bb0305]NO/Learning potential1[@bb0095]YESLearning potential predicted improvement in verbal and visual memoryBaseline cognition2[@bb0190]\
[@bb0185]YESHigher baseline cognition larger improvement in functioning1[@bb0120]YESHigher baseline cognition larger improvement in negative symptoms1[@bb0255]YESHigher baseline cognition larger improvement in cognition2[@bb0270]\
[@bb0305]YESLower baseline cognition larger improvement in cognition1[@bb0305]YESLower baseline cognition larger improvement in functioning3[@bb0115]\
[@bb0220]\
[@bb0265]NO/Cognitive insight1[@bb0305]YESGreater self-reported cognitive problems at baseline associated with larger improvements in cognition1[@bb0065]NO/Baseline functioning2[@bb0120]\
[@bb0185]YESHigher baseline functioning associated with a larger improvement in functioning1[@bb0110]YESHigher baseline functioning associated with higher rates of competitive employment1[@bb0305]YESLower function at baseline associated with\
larger gains on functioning2[@bb0025]\
[@bb0030]YESPeople with poor community function receiving NET + VOC achieved better competitive employment rates and worked more hours than people only in the VOC\
No different outcomes between the conditions in people with higher community functionPsychologicalMotivation1[@bb0125]YESHigher baseline motivational system functioning larger improvements in global cognition and verbal memory1[@bb0270]NO/Self-esteem1[@bb0110]YESHigher baseline self-esteem associated with higher competitive employment and lower unemployment1[@bb0035]NO/Illness-relatedSymptoms2[@bb0115]\
[@bb0305]YESHigher negative and positive symptoms at baseline associated with greater improvement in functioning1[@bb0305]YESHigher negative and positive symptoms at baseline associated with greater improvement in cognition1[@bb0120]YESHigher disorganized PANSS scale associated with greater improvement in cognition1[@bb0120]YESLower scores for the PANSS excited scale, positive and negative symptoms associated with higher functioning improvements and negative symptoms reduction1[@bb0265]YESLower baseline symptoms associated with improvements in cognition and left thalamic volume9[@bb0015]\
[@bb0130]\
[@bb0190]\
[@bb0185]\
[@bb0255]\
[@bb0270]\
[@bb0275]\
[@bb0345]\
[@bb0300]NO/Medication2[@bb0305]\
[@bb0270]YESPeople on a lower antipsychotic dose were more likely to complete the therapy and improve1[@bb0300]YESHigher antipsychotic loads associated with better improvement in verbal learning1[@bb0310]YESSerum anticholinergic activity associated with lower therapy gains1[@bb0345]YESPeople on atypical antipsychotic had larger effects on cognition compared to those on typical antipsychotics1[@bb0350]YESPeople who received clozapine or typical medication had larger response compared to those on atypical medications3[@bb0255]\
[@bb0120]\
[@bb0275]\
[@bb0150]NO/Diagnosis1[@bb0305]YESPeople with schizoaffective disorder had greater improvement in subjective quality of life compared to those with schizophrenia1[@bb0200]NO/Comorbid disorders1[@bb0220]YESComorbid substance abuse was associated with worse employment outcomes1[@bb0220]NOPhysical comorbid condition (e.g. metabolic deficits) was not associated with employment outcomesDuration of illness1[@bb0090]YESPeople with shorter illness duration had better outcomes4[@bb0120]\
[@bb0255]\
[@bb0305]\
[@bb0300]NO/Hospitalisation1[@bb0255]NO/

3.7. Demographic characteristics {#s0080}
--------------------------------

A number of papers reported that gender ([@bb0120]; [@bb0305]; [@bb0345]), education ([@bb0120]; [@bb0255]; [@bb0305]) and age ([@bb0120]; [@bb0145]; [@bb0150]; [@bb0255]; [@bb0345]) were not significant moderators of the effect of CR on therapy outcomes. However, of the studies finding age as a moderator of therapy response, three reported that younger participants benefited more than older in several cognitive domains ([@bb0090]; [@bb0215]; [@bb0360]), negative symptoms and functioning ([@bb0360]). In contrast, four studies found that older participants showed larger improvements in cognition ([@bb0300]; [@bb0305]), self-esteem ([@bb0360]) and, functioning ([@bb0105]) compared to younger. However, in the study conducted by [@bb0105], age was not found as a moderator of the effect of CR on cognition and symptoms.

The generalisability of the demographic factors considered is subject to limitations. There is limited variability in terms of gender \[males were the 75.8% ([@bb0345]), 65.5% ([@bb0120]), 68.6% ([@bb0305])\]. Education was measured using different methods \[years of education ([@bb0255]; [@bb0305]), level of education ([@bb0120])\]. These aspects are likely to affect the quality of the findings and limit the possibility of drawing reliable conclusions. Similarly, in the studies exploring participants\' age, each study compared participants from a different age range \[under 45 years old and age 45 years old or over, mean age is not reported ([@bb0210]); 17--65 years old, mean 36 ([@bb0360]); younger than 25-older than 40, mean 33 ([@bb0090]); 21--69 years old, mean 45 ([@bb0305]); over age 44 vs. under age 45, mean 35.1 ([@bb0300]); 18--60 years of age, mean 39.5 ([@bb0120]); 18--45 years old, mean 33.5 ([@bb0145]); age \<55 years, mean 36 ([@bb0255]); 19--64 years old, mean 38.6 ([@bb0345]); 21--60 years old, mean 47.7 ([@bb0105]); 20--65 years old, mean 46 ([@bb0150])\], making it difficult to compare different results. Another limitation is that these studies have a very narrow range to carry out an analysis, for example, in the study conducted by [@bb0105] while the age range was 21--60 years old, the majority of participants (within one standard deviation above or below mean) were between 40.3 and 53.5 years limiting how these results will apply to those at the extremes of the distribution. In addition, seven studies analysed age as a continuous variable ([@bb0105]; [@bb0120]; [@bb0145]; [@bb0255]; [@bb0300]; [@bb0305]; [@bb0345]) while three studies ([@bb0090]; [@bb0210]; [@bb0360]) considered it as a categorical variable.

3.8. Biological features {#s0085}
------------------------

The studies included highlighted several potential biological moderators including brain structure and genetic variability. Cortical reserve was identified as a moderator although studies used different measures of this concept. Grey matter volume ([@bb0180]), cortical thickness ([@bb0255]), integrity of the right front-occipital fasciculus, right corticospinal tract and, bilateral medial lemnisci ([@bb0295]) were all found to moderate CR outcomes including social cognition, verbal and non-verbal memory, attention/vigilance and executive function. However, [@bb0265] reported that baseline thalamic volume did not moderate improvements in cognition and subcortical volume after CR.

Our searches found two studies investigating genotype as a putative moderator of treatment response. These found differential improvement across variants of the COMT gene in favour of global cognition ([@bb0250]), cognitive flexibility and functioning ([@bb0050]). By contrast, [@bb0070] suggested no significant effect of the COMT genotype on CR response.

Overall the total samples of these brain and genetic studies was small. No study assessed the possibility that the association between brain structure and COMT genotype and CR response could have been confounded by the effect of antipsychotic medications, despite the noted influence of drugs on brain structure and dopaminergic system ([@bb0055]).

3.9. Cognition and functioning {#s0090}
------------------------------

Our search identified different cognitive and functional aspects as possible moderators. These include cognitive difficulties insight, baseline cognition, IQ, learning potential and baseline functioning.

[@bb0305] found that higher self-reported cognitive problems at baseline was associated with larger improvements in cognition after CR. Conversely, [@bb0065] found no difference between people with good or poor cognitive difficulties awareness.

Nine studies evaluated baseline cognition with six finding significant effects and three no effect on CR outcomes ([@bb0115]; [@bb0220]; [@bb0265]). However, those that found significant effects reported an association with different outcomes. In four studies higher baseline cognition was associated with larger improvement in functioning ([@bb0190]; [@bb0185]), negative symptoms ([@bb0120]) and cognition ([@bb0255]) after CR. Conversely, two studies reported that lower initial cognition was associated with larger cognitive improvements ([@bb0270]; [@bb0305]) and functioning ([@bb0305]) after CR.

Of the three studies investigating IQ, one found lower IQ was related to smaller gains ([@bb0140]), one that higher premorbid IQ was related to fewer gains ([@bb0145]) and one reported no difference ([@bb0305]).

Our search identified only one study evaluating learning potential which predicted improvement in verbal and visual memory ([@bb0095]).

Of the six studies investigating baseline functioning, three noted that better functioning was associated with a larger improvement in functioning ([@bb0120]; [@bb0185]) higher competitive employment and lower unemployment ([@bb0110]). In contrast, [@bb0305] found that people with lower function showed larger gains; with this finding confirmed by [@bb0025]. In a more recent study by [@bb0030], people with poor community function receiving CR plus supported employment program had better competitive employment rates and worked more hours than people who only received a supported employment program alone. However, for participants with higher community function at entry to the study CR conferred no extra benefit ([@bb0030]).

The main limitation of this set of studies was the relatively small sample sizes which meant that although they found a significant, the effect size reliability is low. Outcomes were measured with different tests, making the comparison complicated (e.g. in baseline cognition studies [@bb0185] measured verbal learning and memory with the California Verbal Learning Test, whereas [@bb0305] used Hopkins Verbal Learning Test; in functioning, [@bb0120] used Life Skills Profile, [@bb0185] the University of California San Diego Performance-based Skills Assessment and, [@bb0305] Quality of Life Interview; in IQ research, [@bb0140] used the Information subtest of the Wechsler Adult Intelligence Scale, [@bb0145] French National Adult Reading Test).

3.10. Psychological features {#s0095}
----------------------------

Our search identified two psychological factors investigated as possible moderators: motivation, and self-esteem. For motivation, [@bb0125] reported that an individual\'s baseline motivation (assessed by anticipatory and consummatory of pleasure) was associated with improvements in global cognition and verbal memory after therapy. But, [@bb0270], found that motivation (considered both as negative symptoms and intrinsic motivation) had no effect on improvement in problem-solving ability.

Two studies evaluated self-esteem with one showing that higher self-esteem at baseline was associated with better competitive employment and lower unemployment ([@bb0110]) and the other found no influence on cognitive gains ([@bb0035]).

It is, however, important to highlight that an accurate comparison between motivation studies is difficult because each study considered a different facet of motivation and measuring motivation is complex. The studies conducted by [@bb0035] and [@bb0110] also have a modest sample size and an active control group (vocational rehabilitation services) that might have influenced the results.

3.11. Illness-related features {#s0100}
------------------------------

We identified six illness-related factors as possible moderators: symptoms, medication, diagnosis, comorbid disorders, duration of illness and number of hospitalisations. In terms of symptoms, some studies found that higher baseline symptoms severity was associated to larger improvements in functioning ([@bb0115]; [@bb0305]) and cognition ([@bb0120]; [@bb0305]). But others reported that lower baseline symptoms severity was related to better functioning ([@bb0120]), negative symptoms ([@bb0120]), cognition and subcortical volume preservation ([@bb0265]) after therapy. Another nine studies ([@bb0015]; [@bb0130]; [@bb0190]; [@bb0185]; [@bb0255]; [@bb0270]; [@bb0275]; [@bb0300]; [@bb0345]), found no association between baseline symptoms profile and CR outcomes.

Again, these studies had limitations: used different PANSS factor models and participants in different studies had different levels of symptoms. For example, [@bb0305] used the PANSS three-factor structure from [@bb0175] but considered only the Positive (mean 16.0) and Negative dimensions (mean 15.6). [@bb0265] used the same factor structure but considered Positive (mean 12.65), Negative (mean 17.18) and General symptoms (mean 33.32) scores. [@bb0115] used both PANSS three- and five-factor ([@bb0320]), analysing only Negative symptoms (mean 2.7). [@bb0120], instead, considered a 5-factor structure by [@bb0320]; Positive (mean 6.8), Negative (mean 16), Disorganized (mean 8.4) Depressed (mean 6.8) and Excited (mean 5.8).

There were also inconsistencies in how medication influenced therapy outcomes with two studies reporting that those on a lower dose of antipsychotic medication were more likely to complete the therapy ([@bb0305]) and show improvement on problem-solving ([@bb0270]). One study, however, showed the opposite with higher medication levels being associated with improvements in verbal learning ([@bb0300]). [@bb0150] did not find that antipsychotic dose moderated CR outcomes. [@bb0310] found that serum anticholinergic activity, an index of individual\'s anticholinergic burden, contributed by the cumulative effect of drugs and their metabolites, was associated with poorer CR response. A study by [@bb0345] showed that people who received atypical antipsychotic medications showed larger effects on cognition after CR compared to those who had been prescribed typical antipsychotics, but this difference was not maintained at follow-up. In a further study, [@bb0350] reported that people who received either clozapine or typical antipsychotic achieved better results after therapy in comparison with those who received other atypical medications. Finally, three studies showed that medication levels before therapy did not predict CR response for cognition, functioning or symptoms improvements ([@bb0120]; [@bb0255]; [@bb0275]). It is, however, important to highlight that a comparison between these studies is difficult because each study used different medications (e.g. first- and second-generation of antipsychotics).

Diagnosis and additional comorbid disorders are other illness-related aspects identified as possible moderators. We found only one study ([@bb0305]) suggesting that participants with schizoaffective disorder reported greater CR-associated improvement, in subjective quality of life, compared with those with a diagnosis of schizophrenia. However, [@bb0200] did not find the diagnosis as a moderator. [@bb0220], comorbid substance abuse was related to worse employment outcomes, after CR plus vocational rehabilitation and vocational rehabilitation alone, while the presence of a physical comorbid condition (e.g. metabolic deficits) was not associated with work outcomes.

The effects of illness duration on CR outcomes were mixed: with superior CR benefits reported for individuals with shorter illnesses length reported by [@bb0090] but no associations found in four other studies ([@bb0120]; [@bb0255]; [@bb0300]; [@bb0305]). [@bb0255] reported that the number of hospitalisations (mean 1.76) had no effects on CR outcomes. However, there is large variability in participants\' illness duration across these studies making, again, comparisons difficult with average illness length ranging from 9.3 to 20.5 years. There were also differences in the way these studies analysed illness duration with the only study that found an effect considered it as categorical, unlike all other studies that considered illness duration as continuous and found negative results.

4. Discussion {#s0105}
=============

The aim of this study was to review the literature to identify moderators of CR treatment response which can be used to understand why different participants achieve different outcome after CR.

This review identified 18 moderators considered to have an effect on CR; however, we found no high-quality replicated evidence for any of these. The majority of the studies reviewed lacked adequate power to conduct moderation analysis and half of the studies had poor methodological quality are considered at high risk of bias. The variability in the CR approaches and control groups considered might have also played a role in the lack of findings convergence. Studies also measured the same outcomes in different ways, particularly cognition but also functioning, with measures spanning from capacity to role functioning. Further, the studies included in this review considered a large number of moderators for a large number of outcomes. This created a vast amount of research questions which may make the current set of results at risk of reporting false positives. In addition, different individual potential predictors were investigated independently despite the possibility for a combined effect on CR (e.g. learning potential, education, and age).

To move the personalisation agenda of CR forward evidence on moderators needs to be stronger, replicated and based on appropriately powered research. In the section below, we have highlighted some research implications for the field to consider.

4.1. Research implications {#s0110}
--------------------------

While it is well known that positive findings are more likely to be published ([@bb0235]), it is recognised that negative findings play an important role in shaping knowledge advancement. The majority of the studies we reviewed reported positive results. This may be because positive results are more often reported and mentioned in papers. However, it is likely that negative results were found as often but not reported contributing to a "skewed view" of the moderators\' landscape. Future research should consider more routine reporting of negative findings.

As the results of this review show, there is no strong evidence for any of the moderators identified. While this is likely to be due to the lack of rigorous studies, it also shows that the field has, so far, focussed on exploratory studies to identify potential moderators. While this is a necessary first step, what the field needs now is replication and evidence consolidation. This will require large datasets and clear hypothesis-driven studies to test specific moderators and estimate more precisely their effect size on outcomes of interest.

It is also important to consider the mechanisms by which a moderator may act on therapy. Like other psychological therapies, CR relies on factors implicated in learning such as age, IQ, learning potential, motivation, self-esteem, and working alliance. These are hypothesis-based moderators and can be investigated based on a coherent theoretical framework. For example, there is evidence that people with schizophrenia have low self-esteem and that this has a negative impact on engagement and may have a detrimental effect on outcomes ([@bb0075]; [@bb0170]). Self-esteem also affects the perception that people with schizophrenia have about their cognitive difficulties ([@bb0080]). Moderators linked to hypothesised mechanisms of action may be more likely to show consistent trends and be used to understand mechanisms of CR effectively.

Research showed that people with schizophrenia have unique type and severity profiles of cognitive impairment ([@bb0280]). As CR targets cognitive difficulties, it is unclear whether different profiles of cognitive impairment would require different therapies regimes. Using an analogy from medication prescribing, one may hypothesise that more severe impairment may require higher therapy intensity (e.g. dose) or frequency. However, as psychological therapy, CR may respond to a different type of personalisation not necessarily to do with therapy dose and frequency but with ingredient types or dose. It may be that adapting or calibrating training to a particular profile of cognitive impairment may help to improve treatment response. A recent attempt at personalisation in this sense has not proven to be successful ([@bb0145]) but personalisation in this study was done only on one cognitive domain (e.g. executive function). It may be that training programs need to consider personalisation on multiple cognitive domains.

As research on personalisation progresses, it is also important to consider what outcome is the personalisation aiming to improve. A recent study compared different CR training methods targeting executive and perceptual processes ([@bb0045]). Personalisation for perceptual processes programs may be very different to executive programs and research in these two areas may reflect different priorities. One, more research-based and more interested in the underlying mechanism of CR, while the other more clinical and focussed on improving outcomes for people with schizophrenia.

4.2. Limitations {#s0115}
----------------

The studies included have several limitations that can be grouped in main areas:(i)*Generalisability*: While the results in this study are based on a sample\'s characteristics which reflect people with schizophrenia presenting to clinical services, the generalisability of these findings may be subject to limitations. For instance, the majority of the included studies consider samples with a high proportion of male participants and with a restricted range of age (21.2--48.1 years old). While these are likely to be the most common demographics associated with participants taking part in CR studies, it may be difficult to generalise the findings to female and younger or older people. In addition, we included only English-language publications and the majority of the studies considered took place in United States. These aspects may limit the generalisability of our results to other countries and cultures.(ii)*Methodological quality*: The majority of the studies considered lacked independent randomization and/or treatment fidelity assessment. This is a potential source of bias as it may mean that assessor blinding was not rigorously implemented and that participants may have received treatment of variable quality within the same study. Caution should be used in drawing firm conclusions from these studies."(iii)*Measure heterogeneity*: Studies measured the same outcomes using different methods tools, making the comparison and an overall conclusion about the effect of moderators difficult. Future research would benefit for using standardized assessments and well-normed neurocognitive, functional, and symptoms batteries.(iv)*Ratio for study selection*: This review only considered studies that mentioned the assessment of moderators in the abstract. This search strategy might therefore have missed relevant papers where the moderators were assessed but not reported. These moderation analyses were likely to be negative. In addition, it was difficult to ascertain if any moderators were hypothesis-driven or opportunistic as most studies did not have pre-registered analysis plans.(v)Heterogeneity of CR therapy and type of control: The results heterogeneity found in this review may be due to differences in the CR intervention used. These include differences in intervention length, mode of administration (paper and pencil, computer, individual, group), focus of training (single versus multi-domain as well as drill-and-practice versus drill plus strategy training) and whether the intervention is administered as a stand-alone or part of a broader rehabilitation program.

There is also heterogeneity in the control groups with some studies having active control groups (e.g. computer games), others a passive control condition (e.g. treatment as usual), and some studies both. For instance, [@bb0120] used a CR strategy-based training focus on executive function and metacognition, in a group format, with a duration of 16 weeks and consisting of 32 sessions and did not found age as a moderator of CR benefits. On the other hand, [@bb0335], used CR plus treatment-as-usual, 3 days per week until 40 sessions were completed, in an individual format, and with treatment-as-usual as control group and found age as a moderator of treatment response.

In the future, it might be useful to conduct studies using large datasets produced by aggregating data from existing trial to reduce the effect of different therapy programs and control groups. This is what the National Institute for Mental Health is aiming to do by developing the Database of Cognitive Training and Remediation Studies (DoCTRS) (for example of DoCTRS database use [@bb0085]). These data would allow to test mechanisms and moderators of CR with an adequate statistical power and limit the influence of individual studies procedures and control groups on CR outcomes.

5. Conclusion {#s0120}
=============

Even though there is evidence of substantial individual differences in response to CR ([@bb0245]; [@bb0365]), we still have a limited understanding of what causes variability in CR response. This review highlighted five categories of moderators that might influence CR response. We did not find strong evidence in support of any of them. Many significant effects were in opposite directions and most studies were small. The importance of this work is in summarizing the evidence so far accumulated in the field and suggesting moderators to be investigated in future studies. A recommendation is for appropriately powered and hypothesis driven moderation studies. While this may be difficult to achieve in one study, merging data from existing trials may provide the solution. Achieving clear evidence on the role of moderators in CR and using this information for understanding who will benefit more from the therapy relies largely on future studies adhering to good quality methodology and more shared efforts to identify key factors to investigate.
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